Antiparasitic Drugs Market - By Drug Class (Anthelmintics (Benzimidazoles, Pyrantel, Niclosamide, Praziquantel), Antiprotozoals (Antimalarial Drugs-Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, Others), and Other Antiprotozoal Agents), Route of Administration (Oral, Injectable, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Global Opportunity Analysis and Industr

Antiparasitic Drugs Market held USD 7589.3 million in 2020 and is to grow with a CAGR of 5.0% from 2020-2030. The treatment of parasitic infectious diseases involves anthelmintics, antiporozoal and other agents. Antiparasitic drugs are a type of medicines which are widely used for the treatment of parasitic diseases, including those caused by helminths, ectoparasites, parasitic fungi, amoeba, and protozoa. WHO reports that 1,5 billion people worldwide suffered from parasite disease in March 2020. These diseases include GI disorders, anemia, wastage, cognitive deficiencies and childhood development and other infections. Many parasites are life-threatening and others may cause healthy lifestyles discomfort. The WHO estimates that less than 10% of the $56 billion that is spent on health research worldwide each year goes to diseases which affect a 90% population worldwide.  

Market Dynamics and Factors:

The regulatory authority's approvals for antiparasitic drugs are expected to boost the growth of the antiparasitic drugs market share. In addition, different pharmaceutical companies are actively involved in the research and development of novel pharmaceutical entities to treat malaria which is further anticipated to drive the antiparasitic drugs market growth. In November 2017, for example, Novartis Pharmaceuticals began a clinical phase 2 trial to test protection in adult patients with an uncomplicated daily dose of the investigative drug kAE609.

Market Segmentation:

The antiparasitic drugs market size is segmented into by drug class such as anthelmintics which is further divided into benzimidazoles, pyrantel, niclosamide, praziquantel, Antiprotozoal segmented into aminoquinolines, quinoline-methanol. Cinchona alkaloids, biguanides, sulfonamides and sulfones, others, and other antiprotozoal agents. Based on route of administration the anti-parasitic drugs industry is segmented into oral, injectable, and topical. On the basis of distribution channel, the antiparasitic drugs market includes hospital pharmacies, retail pharmacies, and online pharmacies. Geographical breakdown and analysis of each of the aforementioned segments includes regions comprising North America, Europe, Asia-Pacific, and ROW.

Geographic Analysis:

North America is expected to dominate the global antiparasitic drugs market due to growing government focus and development in medical infrastructure. In addition to Asia Pacific and Africa, some areas of North America are affected by parasitic infectious diseases. For example, according to the Centers for Disease Control and Prevention, more than 300,000 people in the U.S. were infected with Trypanosoma Cruzi, a parasite that causes Chagas disease in 2014. In addition, around 300 infants with Trypanosoma Cruzi are born every year in the United States. Developing healthcare infrastructure and increasing investments in Asian countries also acts as supporting factor for the growth of global antiparasitic drugs market size.

Competitive Scenario:

Global antiparasitic drugs market, consists of a few leading players. In terms of market share, some of the major players currently control the chunk of the market. Key companies are also expanding their manufacturing facilities to cater to growing demand for this drug globally. Ipca Laboratories Ltd., Ranbaxy Laboratories, Novartis AG,GlaxoSmithKline Plc., Zydus Cadila, Merck KGaA, Sanofi, Pfizer, Cipla Ltd, Alvizia Health Care, Bayer AG, AstraZeneca plc., Roche Inc., Arbor Pharmaceuticals Inc., and Alkem Laboratories Limited.

Antiparasitic Drugs Market Report Scope